NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
84.48
+0.20 (+0.24%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close84.28
Open85.05
Bid84.91 x 5500
Ask84.99 x 1300
Day's Range84.28 - 85.21
52 Week Range66.93 - 86.90
Volume1,540,361
Avg. Volume1,941,829
Market Cap200.648B
Beta0.73
PE Ratio (TTM)30.84
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.72 (3.22%)
Ex-Dividend Date2017-03-01
1y Target EstN/A
Trade prices are not sourced from all markets
  • Regeneron CEO: Competitor Novartis is 'long on enthusiasm...
    CNBC Videos9 days ago

    Regeneron CEO: Competitor Novartis is 'long on enthusiasm...

    Jim Cramer caught up with Regeneron Pharmaceuticals founder, Chairman and CEO Dr. Leonard Schleifer, who pushed back against his company's rival Novartis.

  • Top 10 Largest Pharmaceutical Companies By Revenue in 2017
    Insider Monkey20 hours ago

    Top 10 Largest Pharmaceutical Companies By Revenue in 2017

    The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]

  • Novartis (NVS) Receives EC Nod for Tasigna Label Expansion
    Zacks2 days ago

    Novartis (NVS) Receives EC Nod for Tasigna Label Expansion

    Novartis (NVS) oncology portfolio gets a boost with EC's approval for the label expansion of Tasigna for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia.

  • Market Realist7 days ago

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold."

  • Market Realist7 days ago

    How Did Novartis Subsidiaries Alcon and Sandoz Perform in 3Q17?

    In 3Q17, Novartis (NVS) subsidiary Alcon generated revenues of $1.5 billion, which was ~6% higher YoY (year-over-year) and 1% higher QoQ.

  • Market Realist7 days ago

    How 2 Key Novartis Oncology Drugs Performed in 3Q17

    In 3Q17, Novartis’s (NVS) Tafinlar-Mekinist generated revenues of $224 million, which was ~30% higher YoY (year-over-year) and 4% higher QoQ.

  • Forbes8 days ago

    CMS Administrator Seema Verma To Outline Her Plan At 2017 Forbes Healthcare Summit

    Seema Verma, the Administrator of the Centers for Medicare and Medicaid Services and a key figure in the future of the Affordable Care Act, will be interviewed live on-stage at the Forbes Healthcare Summit by Forbes Opinion Editor Avik Roy on November 30.

  • Market Realist8 days ago

    Behind 4 Key Novartis Money Makers (and Losers) in 3Q17

    In 3Q17, Novartis’s (NVS) Gleevec generated revenues of $445 million, which was ~47% lower YoY (year-over-year) and ~12% lower QoQ (quarter-over-quarter).

  • Market Realist8 days ago

    How Novartis’s Tasigna Is Looking Now

    In 3Q17, Novartis's (NVS) Tasigna reported revenues of $482 million, which with ~9% higher YoY (year-over-year) and 4% higher QoQ (quarter-over-quarter).

  • Market Realist8 days ago

    Behind Novartis’s Entresto and Gilenya Performances in 3Q17

    In 3Q17, Novartis's (NVS) Entresto generated revenues of $128 million, compared with $53 million in 3Q16. Entresto witnessed a ~16% rise on a QoQ basis.

  • Reuters8 days ago

    Pfizer, Novartis agree UK price cuts for new breast cancer drugs

    Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain's state-funded health service. Both are oral drugs, given in concert with hormonal therapies, that inhibit two proteins called CDK 4 and 6. A third CDK 4/6 drug from Eli Lilly is also licensed in the United States but not yet in Europe.

  • Market Realist9 days ago

    Behind Novartis’s Established Medicine Performance in 3Q17

    In 3Q17, Novartis’s (NVS) Galvus reported revenues of ~$310 million, which was ~1% higher YoY (year-over-year).

  • Market Realist9 days ago

    Behind Novartis’s Respiratory Drug Performance in 3Q17

    In 3Q17, Novartis’s COPD (Chronic Obstructive Pulmonary Disorder) portfolio reported revenues of $165 million, which with ~2% higher YoY and 1% higher QoQ.

  • Market Realist9 days ago

    Inside Novartis’s Ophthalmology Drugs Now

    In 3Q17, Novartis's (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

  • Cramer Remix: My leftover question for GE is 'Did you mislead us or yourselves?'
    CNBC9 days ago

    Cramer Remix: My leftover question for GE is 'Did you mislead us or yourselves?'

    Jim Cramer weighed in on General Electric’s decline and questioned the actions of the company’s management.

  • Market Realist9 days ago

    How Novartis’s Immunology and Dermatology Portfolio Looks after 3Q17

    In 3Q17, Novartis’s (NVS) Neoral generated revenues of ~$126 million, which represents a ~3% YoY (year-over-year) fall and a 2% QoQ fall.

  • Market Realist10 days ago

    How Novartis’s Cosentyx Is Positioned after 3Q17

    In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.

  • Market Realist10 days ago

    How Did Novartis Perform in 3Q17?

    In 3Q17, Novartis (NVS) reported revenues of ~$12.4 billion, which was ~2% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

  • Market Realist10 days ago

    Behind Sanofi’s 3Q17 Revenue Growth

    Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.

  • Novartis (NVS) Arm's Biosimilars Study Results Encourage
    Zacks10 days ago

    Novartis (NVS) Arm's Biosimilars Study Results Encourage

    Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.

  • 3 Top Big Pharma Dividend Stocks You Can Buy Right Now
    Motley Fool10 days ago

    3 Top Big Pharma Dividend Stocks You Can Buy Right Now

    Looking for solid dividend stocks? Check out these big pharma winners.

  • Reuters11 days ago

    Novartis launches heart drug counter-offensive

    Novartis plans to plow through doubts over its canakinumab drug by asking regulators this year to approve the medicine as a treatment for a group of heart attack survivors that the Swiss drugmaker says is most likely to benefit. New analysis of Phase III data shows canakinumab cut risk of another adverse cardiac event by 25 percent in patients whose inflammatory markers fell significantly three months after starting treatment, Novartis said on Monday, adding the group represented 55 percent of those in the so-called Cantos trial. Novartis's trial has been lauded as revolutionary for helping prove fighting inflammation - not merely lowering cholesterol - helps heart attack victims avoid future adverse events or death.

  • Better Buy: Exelixis, Inc. vs. Novartis AG
    Motley Fool12 days ago

    Better Buy: Exelixis, Inc. vs. Novartis AG

    Which stock wins in a head-to-head matchup between a rising biotech star and an established big pharma leader?

  • Reuters13 days ago

    Novartis posts eye drug data amid play for Eylea's turf

    Novartis's (NOVN.S) bid to move in on Bayer's (BAYGn.DE) and Regeneron's (REGN.O) eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea. Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks, Novartis said, of its investigational treatment for wet age-related macular degeneration (AMD), where abnormal, leaky blood vessels can cause blindness. A second, similar study found active disease in 21.9 percent of RTH258 patients versus 31.4 percent of those on Eylea for the condition affecting 20-25 million people worldwide.

  • Reuters13 days ago

    Novartis posts eye drug data amid play for Eylea's turf

    Novartis's bid to move in on Bayer's and Regeneron's eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker's new RTH258 drug showed less disease activity than those on its rivals' drug Eylea. Active disease was observed in 23.5 percent of RTH258 patients versus 33.5 percent of Eylea patients at 16 weeks, Novartis said, of its investigational treatment for wet age-related macular degeneration (AMD), where abnormal, leaky blood vessels can cause blindness. A second, similar study found active disease in 21.9 percent of RTH258 patients versus 31.4 percent of those on Eylea for the condition affecting 20-25 million people worldwide.